Compare Illumina, Inc. (ILMN) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Intel Corp — how do they compare? Illumina, Inc. trades at $189.49 (market cap $27.94B), while Intel Corp trades at $104.6 (market cap $487.82B). The key difference: Intel Corp is far larger — about 17.5× Illumina, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | INTC | |
|---|---|---|
Market Cap | $27.94B | $487.82B |
Sector | Health | Technology |
52-Week High | $194.33 | $140.94 |
52-Week Low | $91.00 | $19.31 |
Enterprise Value | $29.33B | $500.07B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Intel (INTC) trades at $97.87, up 2.97% on the day, with technical indicators showing a bullish overall signal despite mixed moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$267 million in 2025. Recent news highlights volatility in semiconductor stocks amid AI-driven market shifts, with Intel expanding its Google Cloud AI partnership to boost enterprise growth.
Intel's outlook is cautiously optimistic, supported by earnings beats and strategic AI initiatives, but risks include intense competition, margin pressures, and sector volatility. The consensus price target of $109.55 suggests potential upside, though investors must weigh financial recovery against technological challenges in a dynamic chip market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
